Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Roche’s Home Healthcare Medical Device For Anticoagulant Therapy Launches In Europe

XTALKS VITALS NEWS

The Switzerland-based company’s medical device – CoaguChek INRange – monitors a patient’s response to Vitamin K Antagonist (VKA) therapy by measuring blood coagulation.

Share this!

June 2, 2016 | by Sarah Massey, M.Sc.

Roche has launched a new PT/INR home self-testing device for European patients taking anticoagulant drugs Tweet: Roche launches home #medicaldevice for patients taking anticoagulants http://ctt.ec/xovq6+. The home healthcare medical device market is a growing space, and new products have the potential to improve out-of-hospital care for patients.

The Switzerland-based company’s medical device – CoaguChek INRange – monitors a patient’s response to Vitamin K Antagonist (VKA) therapy by measuring blood coagulation. Since the medical device makes use of Bluetooth technology, it could help patients and physicians monitor treatment success more effectively compared to the current standard of care.

Currently, patients must visit a hospital or doctor’s office in order to assess how well they are responding to VKA therapy. The PT/INR testing is done using a blood test, for which lab results could take two to three days to be generated.

Roche’s CoaguChek INRange medical device uses a fingerstick – much like a glucose meter – with results in just 60 seconds. Along with reducing the number of visits to a physician’s office, the medical device could improve patient adherence to a monitoring schedule, thereby improving patient outcomes.



“In a clinical environment, we need to establish a model of care that empowers patients, helping them to understand their health condition and allowing them to take responsibility of their own health care needs,” said Dr. Juan Carlos Souto, of the Hospital de Sant Pau in Barcelona, Spain. “The new technology will enable us to access the test results in the clinic's database, to keep track of the individual patient's status and to measure the quality of care provided by our clinic.”

According to Roche, research has shown that patients using self-testing monitoring devices spend more time at normal INR levels, and may have a lower risk of bleeding and stroke. The company’s home testing medical device could also strengthen the doctor-patient relationship by facilitating communication.

“As healthcare systems face continued pressure to deliver improved access to care at a lower cost, increased connectivity between healthcare providers and patients becomes even more important,” said Roland Diggelmann, COO of Roche Diagnostics. “This is another proof point towards our aim to position patient self-testing as the standard of care to monitor VKA therapy.”


Keywords: Medical Device, Anticoagulant, Home Healthcare


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.